AbbVie Inc (ABBV)vsAC Immune Ltd (ACIU)
ABBV
AbbVie Inc
$288.84
-0.98%
HEALTHCARE · Cap: $521.11B
ACIU
AC Immune Ltd
$2.09
+1.46%
HEALTHCARE · Cap: $220.73M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 376929% more annual revenue ($66.01B vs $17.51M). ABBV leads profitability with a 15.7% profit margin vs -246.5%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
ACIU
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$288.84
$132.00 premium
Intrinsic value data unavailable for ACIU.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 1057.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -210.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : ACIU
The strongest argument for ACIU centers on Revenue Growth, Debt/Equity. Revenue growth of 1057.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : ACIU
The primary concerns for ACIU are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a mature stock while ACIU is a hypergrowth play — different risk/reward profiles.
ACIU carries more volatility with a beta of 1.55 — expect wider price swings.
ACIU is growing revenue faster at 1057.0% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (77/100 vs 24/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
AC Immune Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company is headquartered in Lausanne, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?